Clinical Development of AL002, a Monoclonal Antibody Activating TREM2 Signaling Against Alzheimer’s Disease
Time: 9:00 am
day: Day One
Details:
• Outlining rationale for TREM2 agonism for the treatment of Alzheimer’s Disease
• Exploring target engagement and treatment effects on microglial function
• Evaluating safety and efficacy assessments
